Oncolytic herpes simplex virus (oHSV) has shown efficacy in treating such cancers as GBM, melanoma, breast cancer and ovarian cancer [1] [2] [3] [4] . In 2015, the FDA approved the first oHSV, talimogene laherparepvec (Imlygic), for melanoma treatment 5 . However, the antitumor efficacy of oHSV is diminished in two key ways. First, the host antiviral innate immune response to oHSV infection impairs efficient viral replication and propagation within tumors [6] [7] [8] . Second, intratumoral spread of oHSV is limited by several factors, including the extracellular matrix and areas of fibrosis and necrosis 9 . Previous studies have demonstrated that systemic depletion or inhibition of NK cells significantly improves the efficacy of oHSV treatment for GBM [6] [7] [8] 10 , although the antitumor effect of NK cells is also impaired. Other work has shown that enhancing viral spread improves the efficacy of oHSV [11] [12] [13] . We hypothesized that combining the two strategies could further boost oHSV efficacy, and we aimed to achieve both effects by engineering oHSV to express a molecule that simultaneously blocks cytolytic NK cell activity and promotes viral infectivity.
A r t i c l e s play a larger role than NK cell inhibition in improving the efficacy of OV-CDH1.
RESULTS

E-cadherin expression on GBM cells after OV-CDH1 infection
We generated an oHSV (OV-CDH1) that carries a human E-cadherin coding gene (CDH1) driven by the HSV-1 immediate early gene promoter pIE4/5. The parental oHSV is double-attenuated, with an inactivated ribonucleotide reductase gene (ICP6) and deletions of both copies of the neurovirulence gene (ICP34.5) (Supplementary Fig. 1a ) 21 . These genetic disruptions result in (i) relatively selective viral replication in tumor cells, as proliferating tumor cells compensate for the loss of ICP6 with host ribonucleotide reductase, which is usually low in normal cells, and (ii) a reduction in neurovirulence 22 . The FDA-approved oHSV Imlygic shares a similar backbone 5 . To characterize the role of the extracellular domain of E-cadherin, we also generated a mutant version of OV-CDH1 (OV-IL2RA-CDH1) in which the extracellular domain of E-cadherin was replaced with that of the interleukin-2 receptor α-chain (IL2RA) 23 . The genetic maps of wild-type human HSV-1, parental oHSV (OV-Q1), OV-CDH1 and OV-IL2RA-CDH1 are shown in Supplementary Figure 1a . OV-CDH1 and OV-IL2RA-CDH1 infections introduced the expression of E-cadherin and the IL2RA extracellular domain fused with the E-cadherin intracellular domain into GBM cells, respectively ( Supplementary Fig. 1b-f 
A r t i c l e s
Resistance of OV-CDH1-infected GBM cells to NK cell clearance Given our previous findings 7 , 8 , we next tested the sensitivity of OV-CDH1-infected GBM cells to NK cell-mediated killing. Both OV-Q1 and OV-CDH1 infections increased the susceptibility of GBM cells to NK cell cytotoxicity (Fig. 1a) . However, compared to OV-Q1-infected cells, fewer OV-CDH1-infected cells were killed when cocultured with bulk human primary NK cells (approximately 50% KLRG1 + ) ( Fig. 1a and Supplementary Fig. 2) . Notably, the inhibitory effect was completely abolished with the OV-IL2RA-CDH1-infected human GBM cell line Gli36 as target cells (Supplementary Fig. 3 ). When KLRG1 − NK cells were used as effector cells, there was no difference in killing of OV-Q1-and OV-CDH1-infected GBM cells (Fig. 1b) . However, when KLRG1 + NK cells were used as effector cells, OV-CDH1-infected cells were killed significantly less than OV-Q1-infected cells (Fig. 1b) . Notably, CD107a expression was decreased when KLRG1 + NK cells were incubated with OV-CDH1-infected cells as compared to OV-Q1-infected cells, but there was no difference between comparably cocultured KLRG1 − NK cells (Fig. 1c,d) . We also evaluated NK cell secretion of interferon (IFN)-γ, which can activate macrophages to phagocytose virus-infected cells 24 , and found that KLRG1 + , but not KLRG1 − , NK cells secreted less IFN-γ when cocultured with OV-CDH1-infected cells than with OV-Q1-infected cells (Fig. 1e) .
Enhanced cell-cell fusion and viral spread in OV-CDH1 infection We next evaluated viral spread for OV-CDH1 and found that the GBM-cell plaques formed by OV-CDH1 infection grew much faster and were much larger than those formed by OV-Q1 infection (Fig. 2a,b and Supplementary Videos 1 and 2). These data provide evidence for the enhanced viral spread of OV-CDH1 over that of the parental oHSV, OV-Q1. We further studied the morphological changes within these plaques using distinct staining for cell membranes and nuclei. While OV-Q1-infected cells were mononuclear, with a distinct membrane structure for each cell, multiple nuclei gathered in the central area of OV-CDH1 plaques without obvious cell membrane structure separating them, indicating that the OV-CDH1-infected cells fused together as multinucleated syncytia (Fig. 2c) . Membrane fusion has been previously reported to facilitate viral spread of wildtype HSV-1 (ref. 25) . Using time-lapse plaque formation videos with labeled infected cells, we observed that GFP-positive (OV-CDH1-infected) cells could directly fuse with GFP-negative (uninfected) cells, which subsequently became GFP positive (Supplementary Videos 3 and 4). In contrast, the OV-Q1-infected cells did not fuse with uninfected or infected neighboring cells. Time-lapse phase contrast images showed cell membrane fusion during OV-CDH1 spread ( Supplementary Figs. 4-6 ). Caspase-3/7 staining further indicated that this cell fusion process was initiated with live cells, not dead cells (Supplementary Fig. 7 ). To better mimic the GBM microenvironment, we repeated the plaque formation experiment with semi-solid media containing 1.2% methylcellulose. OV-CDH1 but not OV-Q1 plaques formed in the semi-solid media were larger than those formed in liquid media (Supplementary Fig. 8 ).
Virus-induced E-cadherin is necessary for improved viral spread
To test whether ectopically expressed E-cadherin on OV-CDH1-infected cells contributes to enhanced viral spread, we used a neutralizing antibody that blocks the extracellular domain of E-cadherin 26 .
As predicted, treatment with this antibody resulted in a significant reduction in plaque size after OV-CDH1 (P = 0.008), but not OV-Q1, infection (P = 0.636) (Supplementary Fig. 9 ). To further validate the specific role of the extracellular domain of E-cadherin in this process, we used OV-IL2RA-CDH1 to repeat the plaque formation experiment. Mutant E-cadherin did not induce cell-cell fusion or enhance viral spread (Fig. 3a) . Moreover, there was no significant size difference observed between OV-IL2RA-CDH1 plaques and OV-Q1 plaques (P = 0.538 at 48 hours post-infection (hpi) and P = 0.545 at 72 hpi) (Fig. 3b) . Collectively, these results show that the extracellular domain A r t i c l e s of E-cadherin plays a direct role in triggering cell-cell fusion and enhancing viral spread of OV-CDH1. While GBM cells do not express E-cadherin, they do express N-cadherin, encoded by the gene CDH2, which can interact with E-cadherin to form heterodimers between neighboring cells 27 . We observed colocalization of human E-cadherin and human N-cadherin along the interface between OV-CDH1-infected cells and uninfected cells ( Fig. 3c and Supplementary Fig. 10 ). To determine whether the interaction between E-cadherin and N-cadherin is sufficient to induce cell fusion between OV-CDH1-infected cells and uninfected cells, we knocked down N-cadherin expression in Gli36 cells and performed a plaque formation assay (Fig. 3d) . Knockdown of N-cadherin resulted in a significant decrease in plaque size following OV-CDH1 infection (P = 0.002), but not following OV-Q1 infection (P = 0.839) (Fig. 3e,f) , implying that the interaction between E-cadherin and N-cadherin may contribute to cell-cell fusion between OV-CDH1-infected and uninfected GBM cells and lead to direct cell-to-cell infection.
Improvement of viral production and viral entry by OV-CDH1 We next evaluated the viral production capacity of OV-CDH1-infected cells and found that OV-CDH1 produced significantly more progeny viruses than OV-Q1 following nonsaturating infection in vitro (Fig. 4a,b) . At 48 hpi, the viral production of OV-CDH1 in Gli36 and U251 cells was approximately 17-fold and 13-fold higher than that of OV-Q1, respectively (Fig. 4a,b) . While we did not observe notable differences in viral production of OV-CDH1 and OV-Q1 at late time points (48, 72 and 96 hpi) following saturating infection, there was still 1.5 to 2-fold higher viral production of OV-CDH1 at 24 hpi (Fig. 4c,d) . These results suggest that the enhancement of initial viral entry may also contribute to the higher viral production of OV-CDH1. 
A r t i c l e s
We speculated that if E-cadherin was loaded on the viral membrane of OV-CDH1, it could expedite viral entry. After confirming the loading of E-cadherin on the OV-CDH1 viral membrane ( Supplementary  Fig. 11a-c and Supplementary Note 2) , we tested the viral entry kinetics of OV-CDH1 and OV-Q1 by infecting Gli36 cells. The cells were gently washed with PBS at varying time points following infection (5 to 360 min) to remove unbound viral particles, allowing the viruses that had entered cells to remain and replicate to form plaques. At 48 hpi, plaques were counted as a representation of viral particles that entered the cells and viral entry vs. time curves were established to evaluate viral entry kinetics. Our data suggest that the viral entry speed of OV-CDH1 may be faster than that of OV-Q1 (Fig. 4e) , as only viruses that entered cells could form plaques and there was no viral production difference between OV-Q1 and OV-CDH1 at late time points following saturating infection. A flow cytometry-based kinetics assay for viral binding and entry further supported accelerated viral binding and/or entry of OV-CDH1 ( Supplementary Fig. 11d and Supplementary Note 3).
Enhancement of GBM virotherapy in vivo by OV-CDH1
To evaluate the efficacy of OV-CDH1 on GBM therapy in vivo, we established xenograft GBM mouse models intracranially (i.c.) by injecting luciferase-expressing GBM30 cells or U87∆EGFR cells into athymic nude mice 8 . Five days after tumor implantation, animals were randomly assigned to undergo intratumoral injection with OV-CDH1, OV-Q1 or vehicle control. In the GBM30 model, mice underwent luciferase-based imaging to evaluate the progression of GBM at day 10 ( Fig. 5a ). OV-CDH1 was significantly more effective than OV-Q1 at reducing GBM tumor size in vivo (Fig. 5b,c) . While OV-Q1 moderately slowed GBM progression as compared to vehicle control, all imaged OV-CDH1-treated mice exhibited little to no detectable luciferase signal, suggesting substantial regression of tumor growth. Treatment with OV-CDH1 significantly prolonged the median survival time. Moreover, all but one mouse from the OV-CDH1 group survived over 90 d without GBM symptoms; in contrast, median survival time of mice in the OV-Q1 group was 34 d (Fig. 5d) . Staining of brain sections collected 10 and 20 d after tumor implantation showed that tumors of OV-Q1 treated mice were smaller than those of control mice, but still solid and compact (Fig. 5e) . In OV-CDH1 treated mice, however, no solid tumors were observed (Fig. 5e) . In the more aggressive U87∆EGFR GBM model, OV-CDH1-treated mice still survived significantly longer than OV-Q1-treated mice (Fig. 5f) .
We next sought to evaluate the efficacy of OV-CDH1 in an immunocompetent GBM mouse model. Immunocompetent GBM models to study oHSVs have been challenging to establish because human GBM cells cannot effectively develop tumors in immunocompetent backgrounds and because most murine GBM cells are resistant to oHSV infection [28] [29] [30] (Supplementary Fig. 12a ). To overcome these problems, we used a murine GBM cell line (Gl261N4) engineered to express human nectin-1, a herpesvirus entry receptor 31 . Gl261N4 is thus susceptible to oHSV infection, although to a much lesser extent than human GBM cells ( Supplementary Fig. 12a,b) . Consistent with our previous data, Gl261N4 cells infected with OV-CDH1 showed obvious cell-cell fusion and significantly enhanced viral spread compared to that in Gl261N4 cells infected with OV-Q1 (P < 0.001; Supplementary Fig. 12c,d ). OV-CDH1-infected, but not OV-Q1-infected, Gl261N4 cells expressed E-cadherin on the cell surface, and colocalization of human E-cadherin and murine N-cadherin was observed along the interface between the OV-CDH1-infected cells and uninfected cells ( Supplementary  Fig. 13 ). By i.c. injection of Gl261N4 cells into immunocompetent wildtype C57BL/6 mice, we established a GBM immunocompetent mouse model and repeated the survival study. The treatment of these mice OV-CDH1 at 24 hpi ***P < 0.001; at 48 hpi ***P < 0.001; at 72 hpi ***P < 0.001; at 96 hpi ***P < 0.001. For U251 cells, OV-Q1 vs. OV-CDH1 at 24 hpi *P = 0.035; at 48 hpi ***P < 0.001; at 72 hpi ***P < 0.001; at 96 hpi ***P < 0.001. Unpaired two-tailed t-test after log 2 data transformation (n = 3 technical replicates). (c,d) Gli36 or U251 cells were infected with OV-Q1 or OV-CDH1 at a MOI of 5. At 2 hpi, infection media were replaced with fresh media. At 24, 48, 72 and 96 hpi, supernatant viral titers were measured by plaque assay. Data are presented as mean ± s.d. For Gli36 cells, OV-Q1 vs. OV-CDH1 at 24 hpi *P = 0.024. For U251 cells, OV-Q1 vs. OV-CDH1 at 24 hpi *P = 0.026. Unpaired two-tailed t-test after log 2 data transformation (n = 3 technical replicates). The experiments in a-d were repeated 4 times with similar results. (e) Viral entry kinetics assay of OV-CDH1 and OV-Q1. Monolayer Gli36 cells were infected with 150 PFU of OV-CDH1 or OV-Q1. At 5, 10, 20, 40, 60, 90, 120, 180, 240, 300 and 360 min after infection, infection media were removed and cells were gently washed twice with PBS before semi-solid media were added. At 48 hpi, plaques were counted. Viral entry vs. time curves were established to evaluate the viral entry kinetics of OV-CDH1. The overall group difference in the viral entry kinetics between OV-Q1 and OV-CDH1 was evaluated by a linear model on log 2 transformed data over time (***P < 0.001, n = 3 technical replicates). The experiment in e was repeated 3 times with similar results.
A r t i c l e s
with OV-CDH1 significantly prolonged their median survival (42.5 d) when compared to that of identical mice treated with OV-Q1 (32 d) (Fig. 5g) . Notably, without the extracellular domain of E-cadherin, OV-IL2RA-CDH1 did not produce significant improvement in survival when compared to OV-Q1 (P = 0.760; Supplementary Fig. 14) .
Improvement of viral spread and viral production in vivo by OV-CDH1
To further understand the effects of OV-CDH1 on the tumor microenvironment, we repeated these animal studies with a slightly altered timeline, wherein, to avoid complete tumor eradication, we implanted GBM30 cells and waited for 10 d, followed by a shorter oHSV treatment course of 3 d (Fig. 6a) . In the xenograft model, both OV-Q1 and OV-CDH1 recruited NK cells and macrophages to the brains, but brains treated with OV-CDH1 contained significantly more NK cells (Fig. 6b) . There were no notable differences in macrophage or microglia recruitment between the two viruses (Fig. 6b) . Consistent with our in vitro findings, OV-CDH1 specifically inhibited the cytotoxicity of KLRG1 + but not KLRG1 − NK cells in vivo (Fig. 6c,d) . Similarly, histologic results showed that OV-CDH1 potentiated suppression of A r t i c l e s tumor development (Fig. 6e) . Using immunohistochemical staining with an anti-HSV antibody, we found enhanced viral spread and oncolysis in OV-CDH1-treated mice (Fig. 6f) . Viral production assays further showed that OV-CDH1-treated brains had seven times more viral DNA detected than those treated with OV-Q1 (Fig. 6g) .
In the immunocompetent GBM model, OV-CDH1 resulted in the recruitment of significantly more NK cells, macrophages and microglia as compared to treatment with OV-Q1 (Fig. 6h) . The viral production of OV-CDH1 was also over ten times higher than that of OV-Q1 (Fig. 6i) , which may partially explain why treatment with OV-CDH1 resulted in greater infiltration of NK cells. We also evaluated frequencies of intracranial CD4 + and CD8 + T cells and found that these were significantly increased after both viral treatments, with no difference between the two (Fig. 6j,k) . These in vivo studies not only confirmed OV-CDH1-mediated enhancement of viral spread and production, but also demonstrated an increased infiltration of NK cells, with the cytotoxicity of KLRG1 + NK cells selectively inhibited after OV-CDH1 infection.
Partial contribution of NK cell inhibition in OV-CDH1 virotherapy To better determine the contributions of different immune cells to the improved therapeutic efficacy of OV-CDH1, we repeated the survival studies in the Gl261N4 model with or without depletion of NK cells, macrophages, or CD4 + or CD8 + T cells. In particular, we sought to establish the relative importance of NK cell inhibition in mediating the effects seen with OV-CDH1 treatment. When NK cells were depleted, the survival of both OV-Q1-and OV-CDH1-treated mice was prolonged; however, there was a small but still significant difference in efficacy between OV-CDH1 and OV-Q1 (P = 0.029), suggesting that enhanced viral spread likely plays a larger role than NK cell inhibition in improving the efficacy of OV-CDH1 (Supplementary Fig. 15a ). While macrophage depletion seemed to improve the efficacy of both OV-Q1 and OV-CDH1, the differences in median survival between OV-CDH1-and OV-Q1-treated mice were similar in both the presence and absence of macrophages (Supplementary Fig. 15b ). This might be because the KLRG1 + NK cell subset is not a major source of IFN-γ (Fig. 1e) , a cytokine that activates macrophages. Unlike NK cell or macrophage depletion, CD8 + T cell depletion appeared to lower the therapeutic efficacy of both oHSVs (Supplementary Fig. 15c ). In contrast, CD4 + T cell depletion had no significant influence on survival (P = 0.571 for OV-CDH1 and P = 0.711 for OV-Q1; Supplementary Fig. 15d ).
Safety profiling of OV-CDH1
OV-Q1 and OV-CDH1 both carry the HSV-1 TK gene, which renders the viruses sensitive to the antiviral acyclovir (Supplementary Fig.  16a ), suggesting that viral replication can be stopped effectively as and when needed. To further evaluate the in vivo safety of OV-CDH1, BALB/c mice were intravenously (i.v.) or i.c. injected with wild-type HSV-1 (as a negative control for safety), OV-Q1 or OV-CDH1 at a high dose of 1 × 10 6 plaque-forming units (PFU). Mice injected with i.v. or i.c. wild-type HSV-1 died rapidly (5 d or less) , while all mice treated with OV-Q1 and OV-CDH1 survived to the end of the 4-week study (Supplementary Fig. 16b) . Bio-distribution of OV-CDH1 and OV-Q1 was evaluated using immunohistochemical staining for HSV-1 on sections of the heart, liver, spleen, lung, kidney and brain of mice treated for 2 d, and both viruses exhibited similar patterns (Supplementary Table 1 ). Viral particles were primarily found in the liver and could not be detected in the heart, brain or spleen. We did not observe a discernible tropism change using OV-Q1 and OV-CDH1 infection of six different human primary cells (Supplementary Fig. 17 ).
DISCUSSION
We demonstrate improvement of the therapeutic efficacy of oHSV by reducing its susceptibility to NK cell killing and enhancing its intratumoral spread through overexpression of E-cadherin. oHSV has two different modalities for spreading: viral particle diffusion to infect distant target cells and cell-to-cell infection. In the context of a solid tumor, many factors impair diffusion, and therefore cell-to-cell infection may be the primary mechanism for viral spread. We show that OV-CDH1 forms larger plaques in semi-solid and liquid media via enhanced cell-to-cell infection mediated by E-cadherin. We speculate that overexpressing E-cadherin may strengthen the adherens junctions and shorten the distance between infected and uninfected cells, thus increasing the regional concentration of nectin-1 to facilitate the viral spread.
We and others have demonstrated that NK cell depletion or pretreatment with innate immune suppressive agents before virus administration results in significantly better outcomes in models of GBM, hepatocellular carcinoma and metastatic melanoma 7, 8, 10, [32] [33] [34] . Systemic inhibition of NK cells, however, inevitably causes reduced antitumor activity over the course of treatment. In this study, our goal was to specifically inhibit the antiviral activity of NK cells interacting with oHSV-infected tumor cells while maintaining the inherent OV-CDH1 *P = 0.045 and for KLRG1 − NK cell, uninfected vs. OV-Q1 *P = 0.022, uninfected vs. OV-CDH1 *P = 0.022, by one-way ANOVA with Holm's multiple comparisons test (n = 3 animals). (e,f) Low-magnification H&E-stained (scale bar, 2,000 µm, e) and anti-HSV stained (scale bar, 250 µm, f) coronal brain sections of mice bearing GBM30 tumors. Brown indicated by arrows, HSV-1. Representative images of each group (n = 3 animals) are presented. (g) Virus titers in the brains of the OV-treated nude mice 3 d after OV injection. *P = 0.035 by unpaired two-tailed t-test after log 2 data transformation (n = 3 animals). (h) Intracranial infiltration of NK cells (CD3 − NKp46 + ), macrophages (CD115 + CD45 high CD11b + ) and microglia (CD115 + CD45 low CD11b + ) in Gl261N4-bearing mice measured by flow cytometry 3 d after virus injection. Control vs. OV-Q1, control vs. OV-CDH1, and OV-Q1 vs. OV-CDH1 in NK cell, macrophage and microglia infiltrations: P = 0.154, **P = 0.005, *P = 0.020 and P = 0.237, **P = 0.002, **P = 0.003 and *P = 0.018, **P = 0.001, *P = 0.019, respectively, by one-way ANOVA with Holm's multiple comparisons test (n = 3 animals). (i) Virus titers in the brains of the OV-treated C57BL/6 mice 3 d after virus injection. *P = 0.012 by unpaired two-tailed t-test after log 2 data transformation (n = 3 animals). (j,k) Intracranial infiltration of CD4 + T cells (CD3 + CD4 + ; j) and CD8 + T cells (CD3 + CD8 + ; k) in Gl261N4-bearing mice measured by flow cytometry 3 and 7 days after virus injection (dpi). For CD4 + T cell infiltration, control vs. OV-Q1 and control vs. OV-CDH1: *P = 0.012 and *P = 0.011 at 3 dpi; *P = 0.017 and **P = 0.007 at 7 dpi. For CD8 + T cell infiltration, control vs. OV-Q1 and control vs. OV-CDH1: *P = 0.038 and *P = 0.014 at 3 dpi; *P = 0.025 and *P = 0.024 at 7 dpi. One-way ANOVA with Holm's multiple comparisons test (n = 6 animals). Statistical data are presented as mean ± s.d. throughout.
A r t i c l e s
antitumor activity of the remaining NK cells. While it was previously known that E-cadherin-expressing target cells inhibit the cytotoxicity of tumor-activated NK cells by binding to the receptor KLRG1 (refs. 14-16), it was unclear whether virally activated NK cells could be inhibited by E-cadherin. Here we show that even when NK cells have been activated by oHSV infection, E-cadherin can inhibit the antiviral cytotoxicity of KLRG1 + NK cells by approximately half. This level of inhibition may provide more time for OV-CDH1 to complete viral reproduction and initiate secondary infection, leading to increased tumor killing and thus improving the efficacy of virotherapy. We note that KLRG1 − NK cells produce approximately tenfold more IFN-γ than KLRG1 + NK cells. Activated CD56 bright NK cells are more potent IFN-γ producers while CD56 dim NK cells, which are largely KLRG1 + (Supplementary Fig. 2a) , are more cytolytic 35, 36 . This suggests that, A r t i c l e s compared to inhibition of IFN-γ, inhibition of cytotoxicity by the E-cadherin-KLRG1 interaction is more important in improving the efficacy of OV-CDH1. Consistent with this, our in vivo immune cell depletion data showed that depletion of macrophages, which can be activated by IFN-γ, seemed to nonspecifically enhance the efficacy of both OV-Q1 and OV-CDH1. As GBM is a heterogeneous cancer, we examined the efficacy of OV-CDH1 in three mouse models. OV-CDH1 showed significant improvement over parental OV-Q1 for the treatment of GBM both in the GBM30 and U87∆EGFR xenograft models and in an engineered preclinical GL261 immunocompetent mouse model. In the GBM30 xenograft model, OV-CDH1 treatment resulted in a survival rate of nearly 100% in GBM-bearing mice and nearly eliminated the tumor tissue. Although the U87∆EGFR GBM model is more aggressive owing to the constitutively activated EGFR pathway, we still observed significant enhancement of OV therapy by OV-CDH1. Despite the low susceptibility of Gl261N4 cells to oHSV infection and limited performance of OV-CDH1 in immunocompetent GBM mice, OV-CDH1 treatment still significantly prolonged the survival of Gl261N4 GBMbearing mice when compared to OV-Q1 treatment. The differential efficacies of OV-CDH1 with these three GBM models may be due to intratumoral heterogeneity, which is an important and challenging component of human GBM. In addition to its apparent therapeutic efficacy in our experimental models, we demonstrate that OV-CDH1 possesses sensitivity to the antiviral acyclovir, and it should be sensitive to other antiherpetic agents 37 . This built-in safety feature should allow virus clearance from a patient, if needed, following successful tumor treatment.
Currently, there are two main strategies for oHSV development. One is the attenuation strategy that is used by many oHSVs, including Imlygic, rQNestin34.5 or 34.5ENVE 5, 38, 39 , as well as our OV-CDH1. In this approach, the viruses are modified with deletion or inactivation of some genes involved in viral replication to confine oHSV replication to proliferating tumor cells. However, this results in substantial restriction of viral spread and oncolysis. A second method involves retargeting oHSV to tumor cells by modifying the viral entryrelated glycoproteins [40] [41] [42] . While these viruses maintain potent viral replication and production, the viral entry modifications can reduce viral infectivity 42 . In contrast to both of these approaches, E-cadherin significantly enhanced the viral spread of attenuated oHSV and improved its viral entry, directly contributing to the observed improvement in therapeutic efficacy. We observed enhanced viral spread of OV-CDH1 to occur not only in GBM but also in other solid cancers, including breast cancer (Supplementary Fig. 18 ). This suggests that E-cadherin can be added as a module to other HSVand non-HSV-based oncolytic viruses to improve efficacy in treating cancers other than GBM.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Cells. Human GBM cell lines (Gli36, U251, U87 and U87∆EGFR) and mouse GBM cell lines (Gl261 and Gl261N4) were maintained with DMEM supplemented with 10% FBS, penicillin (100 U/ml) and streptomycin (100 µg/ml). Gl261N4 cells were modified to express human nectin-1 to allow permissiveness to oHSV infection. GBM30 spheroid cells derived from a GBM patient and modified to express luciferase were named GBM30-FFL and used for in vivo imaging. The protocols for human specimen collection were approved by The Ohio State University Institutional Review Board. GBM30 and GBM30-FFL cells were maintained as tumor spheres with Neurobasal medium supplemented with 2% B27 (Gibco), human epidermal growth factor (20 ng/ml) and basic fibroblast growth factor (20 ng/ml) in low-attachment cell culture flasks. Monkey kidney epithelium-derived Vero cells maintained using the same media as the glioblastoma cell lines were used for viral propagation and plaque-assay-based viral titration. To knock down N-cadherin expression in Gli36 cells, the cells were infected with lentivirus encoding N-cadherin shRNA (TRCN0000312701, Sigma). U87, Gli36, U251 and GBM30 cells were authenticated by the University of Arizona Genetics Core via STR profiling in January 2015 and Vero, Gl261 and Gl261N4 cells were not authenticated after receipt. All cell lines were obtained from the laboratory of E. Antonio Chiocca at Harvard Medical School and routinely tested for absence of mycoplasma using the MycoAlert Plus Mycoplasma Detection Kit from Lonza (Walkersville, MD). Human primary cells including oral fibroblasts, pulmonary microvascular endothelial cells, hepatic sinusoidal endothelial cells, pulmonary alveolar epithelial cells, neurons and midbrain neurons were purchased from ScienCell and cultured following manufacturer's instructions.
Viruses. OV-CDH1 and OV-IL2RA-CDH1 were generated using the fHsvQuik-1 system as previously described 21 . Briefly, the full-length coding sequence of the human CDH1 gene was cloned and inserted into pT-oriSIE4/5 following the HSV pIE4/5 promoter to construct pT-oriSIE4/5-CDH1. Then pT-oriSIE4/5 and pT-oriSIE4/5-CDH1 were used to recombine with fHsvQuik-1 to engineer OV-Q1 and OV-CDH1, respectively. To generate OV-IL2RA-CDH1, the original E-cadherin extracellular domain was replaced with the extracellular domain of interleukin-2 receptor alpha chain (IL2RA). The cytoplasmic domain of E-cadherin remained intact 23 . Viruses were propagated and titrated using Vero cells. Virus titration was performed using plaque assays. Briefly, monolayer Vero cells were infected with gradient-diluted viral solutions. Two hours after infection, the infection media were replaced with overlay media containing 1.2% methylcellulose. GFP-positive plaques were counted with a Zeiss fluorescence microscope (AXIO observer Z1) 2 d after infection to calculate the viral titer. The method for concentrating and purifying viruses is described in Supplementary Note 4.
NK cell cytotoxicity assay. U87, Gli36, U251 and GBM30 cells were infected with OV-Q1, OV-CDH1 or OV-IL2RA-CDH1 at a MOI of 5. Eight hours after infection, the infected cells were used as target cells. Effector cells were primary human NK cells isolated from Leukopaks of health donors using an NK cell isolation kit (MACSxpress Miltenyi Biotec, San Diego, CA) and an erythrocyte depletion kit (Miltenyi Biotec). Target cells were labeled with 51 Cr for 1 h and then cocultured with bulk human primary NK cells or sorted KLRG1 + and KLRG1 − NK cells at different effector:target ratios at 37 °C for 4 h. Release of 51 Cr was measured with a LS-6500 Beckman liquid scintillation counter (Beckman Coulter, Fullerton, CA). Target cells incubated in complete media or 1% SDS media were used for spontaneous or maximal 51 Cr release control, respectively. The cell lysis percentages were calculated using the standard formula: 100 × (cpm experimental release -cpm spontaneous release)/(cpm maximal release -cpm spontaneous release). The assays were performed in at least three technical replicates with NK cells from different donors.
Plaque formation assay. To evaluate the viral spreading behavior in OV-CDH1, plaque formation assays were performed using monolayers of U251, Gli36 and Gl261N4 cells that were infected with OV-Q1, OV-CDH1 or OV-IL2RA-CDH1 at a MOI of 0.005. Two hours after infection, the infection media were replaced with fresh media or semi-solid media (1.2% methylcellulose). To investigate the role of E-cadherin in enhancing virus spread of OV-CDH1, the E-cadherin neutralizing antibody (Millipore, MABT26, clone DECMA-1) (100 ng/ml) or the glycoprotein D neutralizing antibody (Abcam, ab27586, clone B007 LP2) (10 ng/ml) was included in the media. For distinct staining, cell components, cell membrane and cell nuclei were labeled using Celltracker Deep Red, CellMask Deep Red and DAPI, respectively, at 24 or 48 hpi. Apoptosis was assessed using CellEvent Caspase-3/7 Red staining at 48 hpi. For the viral tropism assay and cell susceptibility test, gradient (5 to 5,000) PFU of viruses were used for infection. The plaques in each group were imaged using fluorescence microscopy at 24, 48 and 72 hpi or as needed. Videos of plaque formation were recorded with the Zeiss fluorescence microscope (AXIO observer Z1) system from 24 to 72 hpi. Viral production assay. For viral production assays, monolayers of U251 and Gli36 cells were infected with OV-Q1 or OV-CDH1 at MOIs of 5 or 0.005. Two hours after infection, the infection media were replaced with fresh media. The supernatants from each group were then harvested at 24, 48, 72 and 96 hpi and viral titers were determined by plaque assays. The experiments were performed in three technical replicates.
Flow cytometry.
To detect surface expression of human E-cadherin, OV-Q1-and OV-CDH1-infected glioblastoma cells were stained with an anti-hEcadherin-APC antibody (R&D, FAB18381A) for 30 min in Ca 2+ conditional staining buffer. To detect surface expression of human mutant E-cadherin (IL2RA/E-cadherin), an anti-CD25-APC antibody (BD, 340939) was used. For the CD107a degranulation assay, OV-infected or uninfected glioblastoma cells were cocultured with NK cells at the ratio of 1:1 in the presence of an anti-CD107a-PE antibody (BD, 560948) at 8 hpi. One hour later, GolgiStop (BD Biosciences) was added. After 4 h coculture, the cells were harvested and stained with anti-CD56-APC-H7 (Beckman Coulter, B46024), anti-CD3-V450 (BD, 560365) and anti-KLRG1-APC (BioLegend, 368606) antibodies for 30 min. This in vitro CD107a degranulation assay was repeated three times with independent donors. For ex vivo flow cytometric assessment of murine immune cells, mice were killed at the indicated time points. Mononuclear cells in the brain were extracted with Percoll and stained with anti-NKp46 (BD, 560764), anti-CD3 (BD, 552774), anti-CD115 (eBioscience, 12-1152-82), anti-CD45 (eBioscience, 47-0451-82,), anti-CD11b (BD, 557396), anti-CD4 (BD, 552051), anti-CD8 (BD, 553030), anti-KLRG1 (BD, 561620) and anti-CD107a (BD, 558661) antibodies for flow cytometric analysis of immune cells. The flow cytometric assessments of murine immune cells were performed with at least three independent animals. All flow cytometry data were collected using an LSR II cytometer (BD Biosciences). The flow cytometry gating strategy is described in Supplementary Figure 19 .
Animal studies. Six-to eight-week-old female athymic nude mice and C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, Maine). For the survival studies, the mice were anesthetized and stereotactically injected with 1 × 10 5 GBM cells (GBM30-FFL and U87∆EGFR cells for nude mice and Gl261N4 cells for C57BL/6 mice) into the right frontal lobe of the brain (2 mm lateral and 1 mm anterior to bregma at a depth of 3 mm). The GBM cells (GBM30-FFL, U87∆EGFR or Gl261N4) were allowed to grow for 5 d, and animals were subsequently randomly divided into groups that were injected intratumorally either with 2 × 10 5 PFU oHSV (OV-Q1, OV-CDH1 or OV-IL2RA-CDH1) in 3 µl of HBSS or with vehicle. Mice were subsequently monitored frequently for GBM disease progression and were euthanized when they became moribund, with neurologic impairments and obvious weight loss. For the in vivo mechanism study, nude mice and C57BL/6 mice were stereotactically injected with 1 × 10 5 GBM30-FFL or Gl261N4 cells, respectively, into the same site of the brain mentioned above. The GBM cells were allowed to grow for 10 d, and the mice were subsequently intratumorally injected with 2 × 10 5 PFU oHSV (OV-Q1 or OV-CDH1) or vehicle. Three or 7 d after oHSV injection, mice were killed to remove the brain, followed by a flow cytometric assay, viral production assay and immunohistochemistry. The survival studies involving depletions of immune cells were performed using the same Gl261N4 GBM model mentioned above. NK cells were depleted by i.p. injections of NK1.1 neutralizing antibody (BioXcell, BE0036, clone PK136; 0.5 mg/mouse) twice, once on the day before virus injection and once 2 d after the virus injection. Macrophages were depleted by i.p. injections of clodronate liposomes (0.1 ml/mouse) using the same schedule as the NK cell depletion studies. CD4 + and CD8 + T cells were depleted by three i.p. injections of anti-CD4 (BioXcell, BP0003-1, clone GK1.5; 0.5 mg/mouse) and anti-CD8 neutralizing antibodies (BioXcell, BE0004-1, clone 53-6.7; 0.5 mg/mouse), respectively, once every 3 d beginning the day before virus injection. The corresponding isotypes and liposomes were used as controls. All animal work was approved by the Ohio State University Institutional Animal Care and Use Committee.
Immunoblot and quantitative PCR. Western blot was performed as previously described. Anti-hE-cadherin (Millipore, MABT26, clone DECMA-1 and BD, 610181, clone 36/E-cadherin), anti-hN-cadherin (Abcam, ab18203), anti-β-actin (Santa Cruz, sc-1616), anti-HSV (Abcam, ab20536) and the corresponding secondary antibodies (Santa Cruz, sc-2020; GE Healthcare, NA934-1ML, NA931-1ML and GENA935) were used. Viral copy numbers were measured by PCR the primers and probes against glycoprotein D (Forward: 5′-CAGCCCCGCTGGAACTACTAT-3′; Reverse: 5′-TCAGGAACCCCAGGTTATCCT-3′; Probe: VIC-5′-ACAGCTTCAGCGCCG-3′-TAMRA) to evaluate in vivo viral production. Titrated, purified OV-Q1 solution was used as standard control to calculate the viral copy number.
Immunohistochemistry and immunofluorescence assays. Mouse tissue isolated from OV-CDH1-, OV-Q1-or vehicle-treated GBM-bearing mice were placed in 10% neutral buffered formalin for a minimum of 72 h. After paraffin embedding, 4-µm-thick sections were cut from the blocks. Immunofluorescence studies were performed with OV-Q1-and OV-CDH1-infected human (U251) and mouse (Gl261N4) GBM cells at 48 hpi. Antibodies recognizing hE-cadherin (Abcam, ab1416, clone HECD-1) and N-cadherin (CST, 13116, clone D4R1H, recognizing both human and mouse N-cadherin) were used to stain the cells and determine the location of human E-cadherin, human N-cadherin and mouse N-cadherin. 
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Viral entry kinetics assay.
A modified plaque formation assay was performed for measuring viral entry kinetics of OV-CDH1. Briefly, 30,000 Gli36 cells per well were seeded on 96-well plates. The cells were grown overnight, followed by replacing the culture media with fresh media containing 150 PFU of OV-Q1 or OV-CDH1. Infection media were aspirated at 5, 10, 20, 40, 60, 90,120, 180, 240, 300 or 360 min after infection. Following the aspiration of infection media, cells were washed twice with PBS to remove unentered or unbound viruses and then overlay medium with 1.2% methylcellulose was added to cover the cells. This was to keep viruses that had entered cells but to remove unentered or unbound virus, resulting in different groups with different viral incubation times. Forty-eight hours after infection, the number of plaques (GFP positive) were counted with a fluorescence microscope. Data from the OV-Q1 and OV-CDH1 groups were normalized to the respective maximum number of plaques from the 360-min incubation. Viral entry kinetics curves were established by relating the relative plaque numbers to viral incubation time for evaluating the viral entry speeds of OV-Q1 and OV-CDH1.
Statistics. For continuous endpoints that are normally distributed or normally distributed after data transformation (for example, NK cell cytotoxicity, 51 Cr release, IFN-γ levels or viral production), Student's t test was used to compare two independent conditions and one-way ANOVA was used to compare three or more conditions. For data with repeated measures from the same donor (for example, CD107a expression), a linear mixed model was used to account for the variance and covariance structure due to repeated measures. P values were adjusted for multiple comparisons by Holm's procedure. Survival data were estimated by the Kaplan-Meier method and compared by the two-sided log rank test. Nonlinear models were fitted for each treatment group over time by a generalized additive model (R package "mgcv") and the F test was used to compare the residual sum of squares. All tests were two-sided. Data are presented as mean ± s.d. Error bars indicate s.d. A P value of 0.05 or less was considered statistically significant.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article. Data availability. All summary or representative data generated and supporting the findings of this study are available within the paper. Raw data that support the findings of this study are available upon reasonable request.
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Software and code
Policy information about availability of computer code
Data collection
No customized software was used; BD FACSDiva version 6 was used to collect flow cytometric data; Applied Biosystems StepOnePlus real-time PCR system and associated software were used to collect real-time PCR data; microscope data were collected using Zeiss ZEN and associated software (blue edition). Western blot data were collected by FlourChem E system. Additional information about software was described in the manuscript or available upon request.
Data analysis
No custom-made software was used for data analysis. Statistical analyses were performed using R3.4.0, SAS 9.3, Microsoft Excel 2016 or Graphpad Prism 7. The microscope images were analyzed using Zeiss ZEN (blue edition). Flow cytometry data were analyzed using Flowjo 7.6 or 10.0.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. All studies must disclose on these points even when the disclosure is negative.
Sample size
No statistical method was used to predetermine the sample size. Sample sizes in this study were estimated based on previous experience that showed significance. For in vitro studies, the experiments were repeated at least 3 times with samples size at least 3 to control technical variations. For the experiments that using primary human NK cells, experiments were repeated with at least 3 different donors to control biological variations. For survival studies, at least 6 animals for each group were used to obtain informative results.
Data exclusions No data were excluded for all figures.
Replication
All experiments were reliably reproduced and results are represented as mean +/-SD as appropriate, which is indicated in figure legends. Student's t test was utilized to compare two independent conditions and one-way ANOVA model was utilized to compare three or more conditions. For data with repeated measures from the same donor, linear mixed model was utilized to account for the variance-covariance structure due to repeated measures. P values were adjusted for multiple comparisons using Holm's procedure. A P value of 0.05 or less was considered statistically significant, which is described in the methods section of the main text.
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Methodology
Sample preparation Cell population abundance The purity of sorted cells was over 99%.
Gating strategy
To determine E-cadherin expression in GBM cells, live cells were further gated on FSC-A/SSC-A, FSC-H/FSC-W, and then SSC-H/ SSC-W events to check surface expression levels of E-cadherin.
To check surface expression levels of CD107a in enriched human KLRG1(+) and KLRG1 ( 
